|
Treosulfan Clinical Trials
4 actively recruiting trials across 2 locations
▼ -1 trial since May 2026
Also known as: 1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-, Dihydroxybusulfan, Grafapex, Ovastat, Treo +2 more
Pipeline
Phase 2: 3Phase 2/3: 1
Top Sponsors
- St. Anna Kinderkrebsforschung1
- Masonic Cancer Center, University of Minnesota1
- Insel Gruppe AG, University Hospital Bern1
- Fred Hutchinson Cancer Center1
Indications
- Cancer4
- Acute Leukemia2
- Acute Myeloid Leukemia2
- Adult Diffuse Large Cell Lymphoma1
- Refractory Marginal Zone Lymphoma1
Other2 trials
Minneapolis, Minnesota1 trial
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Masonic Cancer Center at University of Minnesota
Phase 2
Seattle, Washington1 trial
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.